American College of Cardiology’s 69th Annual Scientific Session with World Congress of Cardiology (ACC.20/WCC Virtual) – March 28-30, 2020
|Amarin Corp., of Dublin||Vascepa (icosapent ethyl)||Fish oil||Elevated triglycerides||In the phase III Reduce-It study, eicosapentaenoic acid (EPA) increased 400% in patients taking Vascepa compared to placebo (p=1x10^-30); docosahexaenoic acid levels decreased 2.9% (p=0.002); EPA levels strongly correlated to cardiovascular outcomes|
|Mesoblast Ltd., of New York||Revascor||Allogeneic mesenchymal precursor cells||End-stage ischemic heart failure||A substudy of 70 patients with a left ventricular assist device (LVAD) found 64% of patients who received Revascor had temporary weans from LVAD support, compared to 43% of patients who received saline; rate of mucosal bleeding was 4.2 per 100 patient-months for Revascor compared to 28 for saline; readmission rate was 0.59 per 100 patient-days for Revascor compared to 1.14 for saline|
|Resverlogix Corp., of Calgary, Alberta||Apabetalone||Bromodomain and extra-terminal inhibitor||Acute coronary syndrome and type 2 diabetes||In the phase III BETonMACE study, apabetalone treatment reduced hospitalizations for heart failure by 41% compared to placebo; hospitalizations for heart failure and cardiovascular death were reduced by 28%; apabetalone reversed hyperactive pro-inflammatory phenotype ex vivo by down-regulating inflammatory genes and secreted cytokines|
For more information about individual companies and/or products, see Cortellis.